We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.12%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$865M
AUM Growth
+$55.4M
Cap. Flow
-$10.7M
Cap. Flow %
-1.24%
Top 10 Hldgs %
75.1%
Holding
27
New
3
Increased
4
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$63M
2
IMMU
Immunomedics Inc
IMMU
+$47.5M
3
GOSS icon
Gossamer Bio
GOSS
+$39.1M
4
ALLK
Allakos
ALLK
+$32.3M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.2M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$60.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$38.8M
3
WVE icon
Wave Life Sciences
WVE
+$26.4M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$22.1M
5
AMRN
Amarin Corp
AMRN
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 88.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
26
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-600,000
Closed -$60.5M
RETA
27
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-50,000
Closed -$2.81M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Boxer Capital held 27 positions worth $865M, up 6.8% from $809M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Boxer Capital's Q1 2019 filing shows 3 new, 4 increased, 9 reduced and 4 closed positions. Its largest new stake was Biogen: 200,000 shares worth $47.3M. The largest sale was Intercept Pharmaceuticals, Inc., an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 97% a quarter earlier.

  • Boxer Capital's largest Q1 2019 buy was Biogen: 200,000 shares worth $47.3M.
  • Boxer Capital added most to Immunomedics Inc in Q1 2019, an estimated $47.5M increase.
  • Boxer Capital's biggest Q1 2019 reduction was PTC Therapeutics, cutting an estimated $38.8M.
  • Boxer Capital fully exited Intercept Pharmaceuticals, Inc. in Q1 2019, selling an estimated $60.5M.
  • Boxer Capital's ten largest holdings make up 75% of its $865M portfolio in Q1 2019.
  • Boxer Capital opened 3 new positions and closed 4 in Q1 2019.
  • Boxer Capital's portfolio value rose 6.8% quarter-over-quarter to $865M.

Based on Boxer Capital's 13F filing for Q1 2019, filed 15 May 2019.